Clostridium botulinum type a toxin-haemagglutinin complex
Brand: Dysport
PBAC's latest decision on Clostridium botulinum type a toxin-haemagglutinin complex: Recommended with restriction (2020). Considered for Treatment of moderate to severe focal spasticity of the upper limb in patients with cerebral palsy aged 2 years and older.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2007
Submissions
3
2007 → 2020
Eligible population
Children and adults aged 2 years and older with cerebral palsy and moderate to severe focal spasticity of the upper limb.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Indirect comparison
Primary endpoint
Spasticity as measured by Modified Ashworth Scale (MAS), Goal Attainment Scale (GAS), adverse events
Botulinum toxin, type A purified neurotoxin complex (Botox)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated
ICER (historical)
$15k/QALY in an earlier submission (2007) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2007: Recommended with restriction · Restricted — ICER $15k/QALY
Mar 2019: Recommended with restriction · Restricted
Jul 2020: Recommended with restriction · Restricted